2.79
0.11 (3.92%)
Penutupan Terdahulu | 2.68 |
Buka | 2.68 |
Jumlah Dagangan | 219,334 |
Purata Dagangan (3B) | 1,899,582 |
Modal Pasaran | 820,644,800 |
Harga / Jualan (P/S) | 25.96 |
Harga / Buku (P/B) | 0.800 |
Julat 52 Minggu | |
Tarikh Pendapatan | 31 Oct 2024 - 4 Nov 2024 |
Margin Operasi (TTM) | -1,439.42% |
EPS Cair (TTM) | -0.610 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -1.40% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 6.62% |
Nisbah Semasa (MRQ) | 9.34 |
Aliran Tunai Operasi (OCF TTM) | -120.17 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -105.58 M |
Pulangan Atas Aset (ROA TTM) | -13.26% |
Pulangan Atas Ekuiti (ROE TTM) | -15.55% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | AbCellera Biologics Inc. | Menurun | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 3.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | -5.0 |
Osilator Teknikal | 2.0 |
Purata | -0.50 |
AbCellera Biologics Inc is an antibody discovery and development engine that’s specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company’s experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 27.93% |
% Dimiliki oleh Institusi | 39.65% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Founders Fund Vii Management, Llc | 30 Jun 2024 | 3,773,530 |
Guardian Capital Advisors Lp | 30 Jun 2024 | 1,786,414 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 12.00 (Stifel, 330.88%) | Beli |
Median | 8.00 (187.25%) | |
Rendah | 4.00 (Keybanc, 43.63%) | Beli |
Purata | 8.00 (187.25%) | |
Jumlah | 2 Beli | |
Harga Purata @ Panggilan | 2.88 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Keybanc | 08 Jan 2025 | 4.00 (43.63%) | Beli | 3.03 |
Stifel | 05 Nov 2024 | 12.00 (330.88%) | Beli | 2.72 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
13 Jan 2025 | Pengumuman | AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology |
21 Nov 2024 | Pengumuman | AbCellera to Present at Upcoming Investor Conferences in December and January |
07 Nov 2024 | Pengumuman | AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024 |
04 Nov 2024 | Pengumuman | AbCellera Reports Q3 2024 Business Results |
22 Oct 2024 | Pengumuman | AbCellera to Present at Upcoming Investor Conferences in November 2024 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |